Free Trial
NASDAQ:CRTX

Cortexyme (CRTX) Stock Price, News & Analysis

Cortexyme logo
$1.11 +0.02 (+1.83%)
As of 05/23/2025

About Cortexyme Stock (NASDAQ:CRTX)

Key Stats

Today's Range
$1.04
$1.14
50-Day Range
$0.84
$1.40
52-Week Range
$1.78
$40.66
Volume
161,407 shs
Average Volume
620,672 shs
Market Capitalization
$33.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Stock News Headlines

Crism Thera Regulatory News
$19 for a FULL YEAR of stock picks?!
Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. Discover how a $100 investment could give you exposure to Musk's private AI project — via one overlooked stock.
See More Headlines

CRTX Stock Analysis - Frequently Asked Questions

Cortexyme's stock was trading at $1.85 on January 1st, 2025. Since then, CRTX stock has decreased by 40.0% and is now trading at $1.11.
View the best growth stocks for 2025 here
.

Cortexyme, Inc. (NASDAQ:CRTX) released its earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.05.

Cortexyme (CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cortexyme investors own include Alibaba Group (BABA), Enterprise Products Partners (EPD), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Meta Platforms (META) and AT&T (T).

Company Calendar

Last Earnings
8/09/2021
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:CRTX
Fax
N/A
Employees
55
Year Founded
2012

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-89,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.97 per share
Price / Book
0.28

Miscellaneous

Free Float
21,739,000
Market Cap
$33.47 million
Optionable
Not Optionable
Beta
1.40

Social Links

10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:CRTX) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners